These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2007-000394-36 A Phase III randomised, multicentre, double-blind, therapeutic equivalence study of biosimilar G-CSF (PLIVA/Mayne filgrastim) versus Neupogen (filgrastim-Amgen) in subjects receiving doxorubicin and d... 2008-09-30 bad-data
Not reported 2014-005192-89 Post-Marketing Observational Cohort Study of Patients with Inflammatory Bowel Disease (IBD) Treated with CT-P13 in Usual Clinical Practice (CONNECT-IBD) 2018-10-31 due-trials
Exempt, with results 2015-002057-35 A Phase 1-2 ascending dose study to assess the pharmacodynamics, pharmacokinetics, and safety of HSP 130 in subjects with non metastatic breast cancer following single dose and multiple dose administr... 2017-10-05 not-yet-due
Trial is outside EEC, and reported results 2017-000320-10 A Phase III, Randomized, Double-Blind, Dose-Controlled, Multicenter Study Evaluating bad-data
Trial is outside EEC, and reported results 2017-000406-38 A Phase II/III, Open-Label, Multicenter, Safety, Efficacy and Pharmacokinetic Study of bad-data
Trial is outside EEC, and reported results 2017-000407-24 A Phase II, Randomized, Open-Label, Single Center, Pharmacokinetic and bad-data
Trial is outside EEC, and reported results 2017-000408-71 A Phase II/Ill, Open-Label, Multicenter, Safety, and Efficacy Study of Dexmedetomidine in bad-data